加齢性黄斑変性症(AMD)治療薬市場は、2024年の104億6000万ドルから2029年までに173億7000万ドルに成長し、予測期間中に10.7%のCAGRで成長すると予想されます。加齢性黄斑変性症(AMD)治療薬市場の主要企業には、Regeneron Pharmaceuticals Inc. (米国)、Bayer AG (ドイツ)、F. Hoffmann-La Roche Ltd (スイス)、Novartis AG (スイス)、Apellis Pharmaceuticals (米国)、Coherus BioSciences (米国)、アステラス製薬 (日本)、Biogen (米国)、STADA Arzneimittel AG (ドイツ)、Formycon AG(ドイツ)、Bioconが含まれます。(インド)、Outlook Therapeutics, Inc.(米国)、Intas Pharmaceuticals Ltd. (インド)、Teva Pharmaceutical Industries Ltd .(イスラエル)、Chengdu Kanghong Biotech Company (中国)、Sandoz Group AG (スイス)。
目次
TABLE OF CONTENTS
1 INTRODUCTION
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS (Page No. - 53)
4.1 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET OVERVIEW
4.2 NORTH AMERICAN AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET SHARE, BY APPROVAL TYPE AND COUNTRY, 2023
4.3 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2024 VS. 2029 (USD MILLION)
4.4 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2023
4.5 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW (Page No. - 56)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Changing lifestyle and dietary habits
5.2.1.2 Steady development and approvals of drugs
5.2.1.3 Favorable reimbursement and insurance policies
5.2.2 RESTRAINTS
5.2.2.1 Off-label use of drugs
5.2.3 OPPORTUNITIES
5.2.3.1 Shifting focus on new drug modalities
5.2.3.2 Rapidly expanding market in developing countries
5.2.3.3 Need to address dry age-macular degeneration and geographic atrophy
5.2.4 CHALLENGES
5.2.4.1 Non-adherence to treatments
5.3 TECHNOLOGY ANALYSIS
5.3.1 KEY TECHNOLOGIES
5.3.1.1 Hybridoma technology
5.3.1.2 Recombinant DNA technology
5.3.1.3 Antibody engineering
5.3.2 ADJACENT TECHNOLOGIES
5.3.2.1 Tissue engineering (scaffold technology)
5.3.2.2 Artificial intelligence
5.3.2.3 Optogenetic technology
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.5 PRICING ANALYSIS
5.5.1 AVERAGE SELLING PRICING OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY PRODUCT (PER DOSE)
5.5.2 AVERAGE SELLING PRICE OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY REGION
5.5.3 AVERAGE SELLING PRICE OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY KEY PLAYER
5.6 VALUE CHAIN ANALYSIS
5.7 SUPPLY CHAIN ANALYSIS
5.8 ECOSYSTEM ANALYSIS
5.9 PATENT ANALYSIS
5.10 REGULATORY ANALYSIS
5.10.1 REGULATORY LANDSCAPE
5.10.1.1 US
5.10.1.2 Europe
5.10.1.3 Emerging economies
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11 PORTER’S FIVE FORCES ANALYSIS
5.11.1 INTENSITY OF COMPETITIVE RIVALRY
5.11.2 BARGAINING POWER OF SUPPLIERS
5.11.3 BARGAINING POWER OF BUYERS
5.11.4 THREAT OF SUBSTITUTES
5.11.5 THREAT OF NEW ENTRANTS
5.12 KEY CONFERENCES AND EVENTS, 2024-2025
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.13.2 BUYING CRITERIA
5.14 INVESTMENT/FUNDING ACTIVITY
5.15 PIPELINE ANALYSIS
5.16 CASE STUDY ANALYSIS
5.16.1 IMPROVED EFFICACY OF RGX-314 FOR WET AGE-RELATED MACULAR DEGENERATION TREATMENT
5.16.2 ENHANCED EFFICACY OF EYLEA HD FOR WET AGE-RELATED MACULAR DEGENERATION TREATMENT
5.16.3 HIGHER EFFICACY AND SAFETY OF FARICIMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATMENT
5.17 IMPACT OF AI ON AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET
6 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT (Page No. - 95)
6.1 INTRODUCTION
6.2 EYLEA & EYLEA HD
6.2.1 HIGHER PREFERENCE BY OPHTHALMOLOGISTS AND PATIENTS TO SPEED UP GROWTH
6.3 LUCENTIS
6.3.1 PROVEN ABILITY TO IMPROVE VISUAL ACUITY AND RETINAL THICKNESS TO FAVOR GROWTH
6.4 VABYSMO
6.4.1 FAVORABLE APPROVAL FROM GOVERNMENT AUTHORITIES TO SUSTAIN GROWTH
6.5 SYFOVRE
6.5.1 INCREASING PREVALENCE OF ADVANCED DRY AGE-RELATED MACULAR DEGENERATION TO BOOST MARKET
6.6 OTHER PRODUCTS
7 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE (Page No. - 114)
7.1 INTRODUCTION
7.2 AFLIBERCEPT
7.2.1 HIGHER EFFICIENCY IN TREATING RETINAL DISORDERS MARKET TO EXPEDITE GROWTH
7.3 FARICIMAB
7.3.1 FAVORABLE ADOPTION AND OUTCOMES OF RESEARCH STUDIES TO AUGMENT GROWTH
7.4 RANIBIZUMAB
7.4.1 ENHANCED RESULTS COMPARED TO LASER TREATMENT TO DRIVE MARKET
7.5 PEGCETACOPLAN
7.5.1 HIGHER ADOPTION IN TREATING GEOGRAPHIC ATROPHY TO CONTRIBUTE TO GROWTH
7.6 OTHER MOLECULES
8 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE (Page No. - 133)
8.1 INTRODUCTION
8.2 BIOLOGICS
8.2.1 HIGHER CLINICAL VALIDATION AND REGULATORY ADVANTAGES TO SUPPORT GROWTH
8.3 BIOSIMILARS
8.3.1 LOW DEVELOPMENT AND APPROVAL TO FAVOR MARKET GROWTH
9 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD (Page No. - 142)
9.1 INTRODUCTION
9.2 WET AMD
9.2.1 BOOMING GERIATRIC POPULATION TO FACILITATE GROWTH
9.3 DRY AMD
9.3.1 INCREASED RESEARCH & DEVELOPMENT EFFORTS TO PROMOTE GROWTH
10 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER (Page No. - 151)
10.1 INTRODUCTION
10.2 HOSPITALS
10.2.1 GROWING COLLABORATIONS BETWEEN HOSPITALS AND PHARMACEUTICAL COMPANIES TO STIMULATE GROWTH
10.3 LONG-TERM CARE FACILITIES
10.3.1 NEED FOR SUSTAINED MEDICAL SUPERVISION AND SUPPORT FOR CHRONIC CONDITIONS TO FUEL MARKET
10.4 SPECIALTY CENTERS
10.4.1 RISING INCLINATION TOWARD PERSONALIZED TREATMENT PLANS TO ACCELERATE GROWTH
11 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY REGION (Page No. - 163)
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2 US
11.2.2.1 Rising investment in healthcare research & development to propel market
11.2.3 CANADA
11.2.3.1 Favorable government initiatives to aid market growth
11.3 EUROPE
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2 GERMANY
11.3.2.1 Rising focus on clinical research with public-private partnerships to augment growth
11.3.3 UK
11.3.3.1 Ongoing technological advancements to promote growth
11.3.4 FRANCE
11.3.4.1 Growing investments in funding healthcare and allied technology to foster growth
11.3.5 ITALY
11.3.5.1 Comprehensive treatment coverage and funding for new therapies to fuel market
11.3.6 SPAIN
11.3.6.1 Growing number of collaborative projects to favor market growth
11.3.7 NETHERLANDS
11.3.7.1 Increasing focus of clinical trials on biomarkers and hereditary conditions to drive market
11.3.8 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2 CHINA
11.4.2.1 Strategic drug approvals to support market growth
11.4.3 JAPAN
11.4.3.1 Advanced healthcare infrastructure to encourage growth
11.4.4 INDIA
11.4.4.1 Regulatory reforms and aging population to boost market
11.4.5 AUSTRALIA
11.4.5.1 Increasing disease incidence and evolving treatment options to facilitate growth
11.4.6 SOUTH KOREA
11.4.6.1 Supportive regulatory environment to boost market
11.4.7 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.5.2 BRAZIL
11.5.2.1 Increasing rate of visual impairment to sustain growth
11.5.3 MEXICO
11.5.3.1 Growing research initiatives for alternative medicines and nano-based drug delivery system to speed up growth
11.5.4 REST OF LATIN AMERICA
11.6 MIDDLE EAST
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
11.6.2 GCC COUNTRIES
11.6.2.1 Saudi Arabia
11.6.2.1.1 Sustained health coverage and biosimilar drug approvals to propel market
11.6.2.2 UAE
11.6.2.2.1 Increasing focus on technological advancements, ongoing research, and government initiatives to support growth
11.6.2.3 Other GCC Countries
11.6.3 REST OF MIDDLE EAST
11.7 AFRICA
11.7.1 GROWING PREVALENCE OF PATIENT ADVOCACY GROUPS AND REGULATORY IMPROVEMENTS TO DRIVE MARKET
11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA
12 COMPETITIVE LANDSCAPE (Page No. - 247)
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGY/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET
12.3 REVENUE ANALYSIS, 2021-2023
12.4 MARKET SHARE ANALYSIS, 2023
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
12.5.5.1 Company footprint
12.5.5.2 Molecule footprint
12.5.5.3 Approval footprint
12.5.5.4 Type of AMD footprint
12.5.5.5 Region footprint
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
12.7 COMPANY VALUATION AND FINANCIAL METRICS
12.7.1 COMPANY VALUATION
12.7.2 FINANCIAL METRICS
12.8 BRAND/PRODUCT COMPARISON
12.9 COMPETITIVE SCENARIO
12.9.1 PRODUCT LAUNCHES & APPROVALS
12.9.2 DEALS
12.9.3 EXPANSIONS
13 COMPANY PROFILES (Page No. - 272)
13.1 KEY PLAYERS
13.1.1 F. HOFFMANN-LA ROCHE LTD
13.1.1.1 Business overview
13.1.1.2 Products offered
13.1.1.3 Recent developments
13.1.1.3.1 Product launches & approvals
13.1.1.4 MnM view
13.1.1.4.1 Right to win
13.1.1.4.2 Strategic choices
13.1.1.4.3 Weaknesses and competitive threats
13.1.2 REGENERON PHARMACEUTICALS INC.
13.1.2.1 Business overview
13.1.2.2 Products offered
13.1.2.3 Recent developments
13.1.2.3.1 Product launches & approvals
13.1.2.4 MnM view
13.1.2.4.1 Right to win
13.1.2.4.2 Strategic choices
13.1.2.4.3 Weaknesses and competitive threats
13.1.3 NOVARTIS AG
13.1.3.1 Business overview
13.1.3.2 Products offered
13.1.3.3 Recent developments
13.1.3.3.1 Product launches & approvals
13.1.3.3.2 Deals
13.1.3.4 MnM view
13.1.3.4.1 Right to win
13.1.3.4.2 Strategic choices
13.1.3.4.3 Weaknesses and competitive threats
13.1.4 BAYER AG
13.1.4.1 Business overview
13.1.4.2 Products offered
13.1.4.3 Recent developments
13.1.4.3.1 Product launches & approvals
13.1.4.4 MnM view
13.1.4.4.1 Right to win
13.1.4.4.2 Strategic choices
13.1.4.4.3 Weaknesses and competitive threats
13.1.5 APELLIS PHARMACEUTICALS
13.1.5.1 Business overview
13.1.5.2 Products offered
13.1.5.3 Recent developments
13.1.5.3.1 Product launches & approvals
13.1.5.3.2 Deals
13.1.5.4 MnM view
13.1.5.4.1 Right to win
13.1.5.4.2 Strategic choices
13.1.5.4.2.1 Weaknesses and competitive threats
13.1.6 ASTELLAS PHARMA INC.
13.1.6.1 Business overview
13.1.6.2 Products offered
13.1.6.3 Recent developments
13.1.6.3.1 Product launches & approvals
13.1.6.3.2 Deals
13.1.7 STADA ARZNEIMITTEL AG
13.1.7.1 Business overview
13.1.7.2 Products offered
13.1.7.3 Recent developments
13.1.7.3.1 Product launches & approvals
13.1.7.3.2 Deals
13.1.8 BIOGEN
13.1.8.1 Business overview
13.1.8.2 Products offered
13.1.8.3 Recent developments
13.1.8.3.1 Product launches & approvals
13.1.9 FORMYCON AG
13.1.9.1 Business overview
13.1.9.2 Product offered
13.1.9.3 Recent developments
13.1.9.3.1 Product launches & approvals
13.1.9.3.2 Deals
13.1.10 COHERUS BIOSCIENCES
13.1.10.1 Business overview
13.1.10.2 Products offered
13.1.10.3 Recent developments
13.1.10.3.1 Products launches & approvals
13.1.10.3.2 Other developments
13.1.11 BIOCON
13.1.11.1 Business overview
13.1.11.2 Product offered
13.1.11.3 Recent developments
13.1.11.3.1 Product launches & approvals
13.1.11.3.2 Deals
13.1.12 OUTLOOK THERAPEUTICS, INC.
13.1.12.1 Business overview
13.1.12.2 Products offered
13.1.12.3 Recent developments
13.1.12.3.1 Product launches & approvals
13.1.12.3.2 Deals
13.1.13 TEVA PHARMACEUTICAL INDUSTRIES LTD.
13.1.13.1 Business overview
13.1.13.2 Product offered
13.1.13.3 Recent developments
13.1.13.3.1 Product launches & approvals
13.1.13.3.2 Deals
13.1.14 INTAS PHARMACEUTICALS LTD.
13.1.14.1 Business overview
13.1.14.2 Products offered
13.1.15 SANDOZ GROUP AG
13.1.15.1 Business overview
13.1.15.2 Products offered
13.1.15.3 Recent developments
13.1.15.3.1 Product launches & approvals
13.1.15.3.2 Deals
13.1.15.3.3 Expansions
13.1.16 CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD.
13.1.16.1 Business overview
13.1.16.2 Products offered
13.2 OTHER PLAYERS
13.2.1 OCULAR THERAPEUTIX, INC.
13.2.2 OPTHEA LIMITED
13.2.3 KODIAK SCIENCES INC.
13.2.4 BIO-THERA
13.2.5 AMGEN INC.
13.2.6 ALVOTECH
13.2.7 STEALTH BIOTHERAPEUTICS INC.
13.2.8 ALTEOGEN INC.
13.2.9 OCUMENSION THERAPEUTICS
13.2.10 INNOVENT
13.2.11 SHANGHAI HENLIUS BIOTECH, INC.
14 APPENDIX (Page No. - 328)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
LIST OF TABLES (379 TABLES)
TABLE 1 INCLUSIONS AND EXCLUSIONS
TABLE 2 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
TABLE 3 AVERAGE SELLING PRICE OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY PRODUCT (PER DOSE), 2021-2023 (USD)
TABLE 4 AVERAGE SELLING PRICE OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY KEY PLAYER, 2021-2023 (USD)
TABLE 5 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
TABLE 6 PATENTS FILED, BY DOCUMENT TYPE, 2014-2024
TABLE 7 INNOVATIONS AND PATENT REGISTRATIONS, 2019-2023
TABLE 8 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 14 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: KEY CONFERENCES AND EVENTS, 2024-2025
TABLE 15 BUYING CRITERIA FOR AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY END USER
TABLE 16 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS IN CLINICAL PIPELINE, PHASE
TABLE 17 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 18 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2023-2029 (MILLION UNITS)
TABLE 19 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY REGION, 2022-2029 (USD MILLION)
TABLE 20 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 21 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 22 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 23 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 24 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY REGION, 2022-2029 (USD MILLION)
TABLE 25 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR EYLEA & EYLEA HD, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 26 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY REGION, 2022-2029 (USD MILLION)
TABLE 27 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 28 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 29 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 30 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 31 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY REGION, 2022-2029 (USD MILLION)
TABLE 32 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LUCENTIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 33 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY REGION, 2022-2029 (USD MILLION)
TABLE 34 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 35 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 36 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 37 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 38 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY REGION, 2022-2029 (USD MILLION)
TABLE 39 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR VABYSMO, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 40 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY REGION, 2022-2029 (USD MILLION)
TABLE 41 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 42 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 43 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 44 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 45 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY REGION, 2022-2029 (USD MILLION)
TABLE 46 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SYFOVRE, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 47 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 48 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 49 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 50 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 51 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 52 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 53 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 54 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 55 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY REGION, 2022-2029 (USD MILLION)
TABLE 56 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 57 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 58 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 59 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 60 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY REGION, 2022-2029 (USD MILLION)
TABLE 61 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 62 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY REGION, 2022-2029 (USD MILLION)
TABLE 63 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 64 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 65 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 66 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 67 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY REGION, 2022-2029 (USD MILLION)
TABLE 68 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 69 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY REGION, 2022-2029 (USD MILLION)
TABLE 70 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 71 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 72 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 73 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 74 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY REGION, 2022-2029 (USD MILLION)
TABLE 75 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 76 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY REGION, 2022-2029 (USD MILLION)
TABLE 77 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 78 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 79 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 80 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 81 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY REGION, 2022-2029 (USD MILLION)
TABLE 82 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR PEGCETACOPLAN, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 83 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY REGION, 2022-2029 (USD MILLION)
TABLE 84 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 85 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 86 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 87 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 88 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY REGION, 2022-2029 (USD MILLION)
TABLE 89 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 90 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
TABLE 91 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY REGION, 2022-2029 (USD MILLION)
TABLE 92 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 93 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 94 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 95 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 96 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY REGION, 2022-2029 (USD MILLION)
TABLE 97 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOLOGICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 98 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY REGION, 2022-2029 (USD MILLION)
TABLE 99 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 100 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 101 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 102 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 103 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY REGION, 2022-2029 (USD MILLION)
TABLE 104 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR BIOSIMILARS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 105 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
TABLE 106 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY REGION, 2022-2029 (USD MILLION)
TABLE 107 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 108 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 109 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 110 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 111 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY REGION, 2022-2029 (USD MILLION)
TABLE 112 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR WET AMD, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 113 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY REGION, 2022-2029 (USD MILLION)
TABLE 114 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 115 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 116 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 117 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 118 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY REGION, 2022-2029 (USD MILLION)
TABLE 119 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR DRY AMD, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 120 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 121 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY REGION, 2022-2029 (USD MILLION)
TABLE 122 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 123 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 124 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 125 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 126 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY REGION, 2022-2029 (USD MILLION)
TABLE 127 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 128 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022-2029 (USD MILLION)
TABLE 129 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 130 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 131 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 132 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 133 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022-2029 (USD MILLION)
TABLE 134 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 135 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY REGION, 2022-2029 (USD MILLION)
TABLE 136 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 137 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 138 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 139 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 140 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY REGION, 2022-2029 (USD MILLION)
TABLE 141 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 142 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 143 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 144 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 145 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
TABLE 146 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
TABLE 147 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 148 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 149 MACROECONOMIC OUTLOOK FOR AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET IN NORTH AMERICA
TABLE 150 US HEALTHCARE SPENDING, 2020-2022 (USD MILLION)
TABLE 151 US: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 152 US: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 153 US: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
TABLE 154 US: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
TABLE 155 US: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 156 CANADA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 157 CANADA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 158 CANADA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
TABLE 159 CANADA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
TABLE 160 CANADA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 161 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 162 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 163 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
TABLE 164 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
TABLE 165 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 166 EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 167 MACROECONOMIC OUTLOOK FOR AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET IN EUROPE
TABLE 168 GERMANY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 169 GERMANY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 170 GERMANY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
TABLE 171 GERMANY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
TABLE 172 GERMANY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 173 UK: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 174 UK: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 175 UK: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
TABLE 176 UK: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
TABLE 177 UK: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 178 FRANCE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 179 FRANCE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 180 FRANCE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
TABLE 181 FRANCE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
TABLE 182 FRANCE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 183 ITALY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 184 ITALY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 185 ITALY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
TABLE 186 ITALY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
TABLE 187 ITALY: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 188 SPAIN: AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 189 SPAIN: AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 190 SPAIN: AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
TABLE 191 SPAIN: AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
TABLE 192 SPAIN: AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 193 NETHERLANDS: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 194 NETHERLANDS: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 195 NETHERLANDS: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
TABLE 196 NETHERLANDS: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
TABLE 197 NETHERLANDS: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 198 REST OF EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 199 REST OF EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 200 REST OF EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
TABLE 201 REST OF EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
TABLE 202 REST OF EUROPE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 203 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 204 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 205 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
TABLE 206 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
TABLE 207 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 208 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 209 MACROECONOMIC OUTLOOK FOR AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET IN ASIA PACIFIC
TABLE 210 CHINA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 211 CHINA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 212 CHINA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
TABLE 213 CHINA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
TABLE 214 CHINA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 215 JAPAN: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 216 JAPAN: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 217 JAPAN: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
TABLE 218 JAPAN: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
TABLE 219 JAPAN: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 220 INDIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 221 INDIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 222 INDIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
TABLE 223 INDIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
TABLE 224 INDIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 225 AUSTRALIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 226 AUSTRALIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 227 AUSTRALIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
TABLE 228 AUSTRALIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
TABLE 229 AUSTRALIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 230 SOUTH KOREA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 231 SOUTH KOREA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 232 SOUTH KOREA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
TABLE 233 SOUTH KOREA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
TABLE 234 SOUTH KOREA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 235 REST OF ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 236 REST OF ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 237 REST OF ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
TABLE 238 REST OF ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
TABLE 239 REST OF ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 240 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 241 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 242 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
TABLE 243 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
TABLE 244 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 245 LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 246 MACROECONOMIC OUTLOOK FOR AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET IN LATIN AMERICA
TABLE 247 BRAZIL: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 248 BRAZIL: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 249 BRAZIL: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
TABLE 250 BRAZIL: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
TABLE 251 BRAZIL: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 252 MEXICO: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 253 MEXICO: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 254 MEXICO: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
TABLE 255 MEXICO: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
TABLE 256 MEXICO: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 257 REST OF LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 258 REST OF LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 259 REST OF LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
TABLE 260 REST OF LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
TABLE 261 REST OF LATIN AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 262 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 263 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 264 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
TABLE 265 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
TABLE 266 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 267 MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 268 MACROECONOMIC OUTLOOK FOR AGE-RELATED MACULAR DEGENERATION (AMD) DRUSG MARKET IN MIDDLE EAST
TABLE 269 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 270 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 271 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
TABLE 272 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
TABLE 273 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 274 GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 275 SAUDI ARABIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 276 SAUDI ARABIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 277 SAUDI ARABIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
TABLE 278 SAUDI ARABIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
TABLE 279 SAUDI ARABIA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 280 UAE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 281 UAE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 282 UAE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
TABLE 283 UAE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
TABLE 284 UAE: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 285 OTHER GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 286 OTHER GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 287 OTHER GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
TABLE 288 OTHER GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
TABLE 289 OTHER GCC COUNTRIES: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 290 REST OF MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 291 REST OF MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 292 REST OF MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
TABLE 293 REST OF MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
TABLE 294 REST OF MIDDLE EAST: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 295 AFRICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 296 AFRICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2022-2029 (USD MILLION)
TABLE 297 AFRICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY APPROVAL TYPE, 2022-2029 (USD MILLION)
TABLE 298 AFRICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2022-2029 (USD MILLION)
TABLE 299 AFRICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 300 MACROECONOMIC OUTLOOK FOR AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET IN AFRICA
TABLE 301 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET
TABLE 302 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: DEGREE OF COMPETITION
TABLE 303 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: MOLECULE FOOTPRINT
TABLE 304 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: APPROVAL TYPE FOOTPRINT
TABLE 305 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: TYPE OF AMD FOOTPRINT
TABLE 306 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: REGION FOOTPRINT
TABLE 307 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 308 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
TABLE 309 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
TABLE 310 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: DEALS, JANUARY 2021- AUGUST 2024
TABLE 311 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: EXPANSIONS, JANUARY 2021-AUGUST 2024
TABLE 312 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
TABLE 313 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
TABLE 314 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
TABLE 315 REGENERON PHARMACEUTICALS INC.: COMPANY OVERVIEW
TABLE 316 REGENERON PHARMACEUTICALS INC.: PRODUCTS OFFERED
TABLE 317 REGENERON PHARMACEUTICALS INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
TABLE 318 NOVARTIS AG: COMPANY OVERVIEW
TABLE 319 NOVARTIS AG: PRODUCTS OFFERED
TABLE 320 NOVARTIS AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
TABLE 321 NOVARTIS AG: DEALS, JANUARY 2021-AUGUST 2024
TABLE 322 BAYER AG: COMPANY OVERVIEW
TABLE 323 BAYER AG: PRODUCTS OFFERED
TABLE 324 BAYER AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
TABLE 325 APELLIS PHARMACEUTICALS: COMPANY OVERVIEW
TABLE 326 APELLIS PHARMACEUTICALS: PRODUCTS OFFERED
TABLE 327 APELLIS PHARMACEUTICALS: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
TABLE 328 APELLIS PHARMACEUTICALS: DEALS, JANUARY 2021-AUGUST 2024
TABLE 329 ASTELLAS PHARMA INC.: COMPANY OVERVIEW
TABLE 330 ASTELLAS PHARMA INC.: PRODUCTS OFFERED
TABLE 331 ASTELLAS PHARMA INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
TABLE 332 ASTELLAS PHARMA INC.: DEALS, JANUARY 2021-AUGUST 2024
TABLE 333 STADA ARZNEIMITTEL AG: COMPANY OVERVIEW
TABLE 334 STADA ARZNEIMITTEL AG: PRODUCTS OFFERED
TABLE 335 STADA ARZNEIMITTEL AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
TABLE 336 STADA ARZNEIMITTEL AG: DEALS, JANUARY 2021-AUGUST 2024
TABLE 337 BIOGEN: COMPANY OVERVIEW
TABLE 338 BIOGEN: PRODUCTS OFFERED
TABLE 339 BIOGEN: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
TABLE 340 FORMYCON AG: COMPANY OVERVIEW
TABLE 341 FORMYCON AG: PRODUCTS OFFERED
TABLE 342 FORMYCON AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
TABLE 343 FORMYCON AG: DEALS, JANUARY 2021-AUGUST 2024
TABLE 344 COHERUS BIOSCIENCES: COMPANY OVERVIEW
TABLE 345 COHERUS BIOSCIENCES: PRODUCTS OFFERED
TABLE 346 COHERUS BIOSCIENCES: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
TABLE 347 COHERUS BIOSCIENCES: OTHER DEVELOPMENTS, JANUARY 2021-AUGUST 2024
TABLE 348 BIOCON: COMPANY OVERVIEW
TABLE 349 BIOCON: PRODUCTS OFFERED
TABLE 350 BIOCON: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
TABLE 351 BIOCON: DEALS, JANUARY 2021-AUGUST 2024
TABLE 352 OUTLOOK THERAPEUTICS, INC.: COMPANY OVERVIEW
TABLE 353 OUTLOOK THERAPEUTICS, INC.: PRODUCTS OFFERED
TABLE 354 OUTLOOK THERAPEUTICS, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
TABLE 355 OUTLOOK THERAPEUTICS, INC.: DEALS, JANUARY 2021-AUGUST 2024
TABLE 356 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
TABLE 357 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
TABLE 358 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
TABLE 359 TEVA PHARMACEUTICAL INDUSTRIES LTD.: DEALS, JANUARY 2021-AUGUST 2024
TABLE 360 INTAS PHARMACEUTICALS LTD.: COMPANY OVERVIEW
TABLE 361 INTAS PHARMACEUTICALS LTD.: PRODUCTS OFFERED
TABLE 362 SANDOZ GROUP AG: COMPANY OVERVIEW
TABLE 363 SANDOZ GROUP AG: PRODUCTS OFFERED
TABLE 364 SANDOZ GROUP AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-AUGUST 2024
TABLE 365 SANDOZ GROUP AG: DEALS, JANUARY 2021-AUGUST 2024
TABLE 366 SANDOZ GROUP AG: EXPANSIONS, JANUARY 2021-AUGUST 2024
TABLE 367 CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD.: COMPANY OVERVIEW
TABLE 368 CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD.: PRODUCTS OFFERED
TABLE 369 OCULAR THERAPEUTIX, INC.: COMPANY OVERVIEW
TABLE 370 OPTHEA LIMITED: COMPANY OVERVIEW
TABLE 371 KODIAK SCIENCES INC.: COMPANY OVERVIEW
TABLE 372 BIO-THERA: COMPANY OVERVIEW
TABLE 373 AMGEN INC.: COMPANY OVERVIEW
TABLE 374 ALVOTECH: COMPANY OVERVIEW
TABLE 375 STEALTH BIOTHERAPEUTICS INC.: COMPANY OVERVIEW
TABLE 376 ALTEOGEN INC.: COMPANY OVERVIEW
TABLE 377 OCUMENSION THERAPEUTICS: COMPANY OVERVIEW
TABLE 378 INNOVENT: COMPANY OVERVIEW
TABLE 379 SHANGHAI HENLIUS BIOTECH, INC.: COMPANY OVERVIEW
LIST OF FIGURES (54 FIGURES)
FIGURE 1 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET SEGMENTATION
FIGURE 2 RESEARCH DESIGN
FIGURE 3 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2023
FIGURE 5 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: REVENUE SHARE ANALYSIS, 2023
FIGURE 6 ILLUSTRATIVE EXAMPLE OF F. HOFFMANN-LA ROCHE LTD: COMPANY REVENUE SHARE ANALYSIS, 2023
FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS
FIGURE 8 BOTTOM-UP APPROACH
FIGURE 9 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: CAGR PROJECTIONS, 2024-2029
FIGURE 10 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: GROWTH ANALYSIS OF MARKET DYNAMICS
FIGURE 11 DATA TRIANGULATION
FIGURE 12 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
FIGURE 13 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY MOLECULE, 2024 VS. 2029 (USD MILLION)
FIGURE 14 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF AMD, 2024 VS. 2029 (USD MILLION)
FIGURE 15 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY TYPE OF APPROVAL, 2024 VS. 2029 (USD MILLION)
FIGURE 16 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 17 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET, BY REGION, 2024-2029
FIGURE 18 GROWING GERIATRIC POPULATION AND CHANGING LIFESTYLE TO DRIVE MARKET
FIGURE 19 BIOLOGICS SEGMENT AND US DOMINATED NORTH AMERICAN MARKET IN 2023
FIGURE 20 WET AMD SEGMENT TO LEAD MARKET BY 2029
FIGURE 21 HOSPITALS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
FIGURE 22 NORTH AMERICA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
FIGURE 23 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 24 REVENUE SHIFT & NEW POCKETS FOR AGE-RELATED MACULAR DEGENERATION THERAPY PROVIDERS
FIGURE 25 AVERAGE SELLING PRICE OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS, BY REGION, 2021-2023 (USD)
FIGURE 26 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: VALUE CHAIN ANALYSIS
FIGURE 27 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 28 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: ECOSYSTEM ANALYSIS
FIGURE 29 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: PATENT ANALYSIS, 2014-2024
FIGURE 30 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS
FIGURE 32 KEY BUYING CRITERIA, BY END USER
FIGURE 33 IMPACT OF ARTIFICIAL INTELLIGENCE ON AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET
FIGURE 34 NORTH AMERICA: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET SNAPSHOT
FIGURE 35 ASIA PACIFIC: AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET SNAPSHOT
FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS, 2021-2023 (USD MILLION)
FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2023
FIGURE 38 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
FIGURE 39 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: COMPANY FOOTPRINT
FIGURE 40 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 42 EV/EBITDA OF KEY VENDORS
FIGURE 43 AGE-RELATED MACULAR DEGENERATION (AMD) DRUGS MARKET: BRAND/PRODUCT COMPARISON
FIGURE 44 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2023)
FIGURE 45 REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT (2023)
FIGURE 46 NOVARTIS AG: COMPANY SNAPSHOT (2023)
FIGURE 47 BAYER AG: COMPANY SNAPSHOT (2023)
FIGURE 48 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2023)
FIGURE 49 STADA ARZNEIMITTEL AG: COMPANY SNAPSHOT (2023)
FIGURE 50 BIOGEN: COMPANY SNAPSHOT (2023)
FIGURE 51 FORMYCON AG: COMPANY SNAPSHOT (2023)
FIGURE 52 BIOCON: COMPANY SNAPSHOT (2023)
FIGURE 53 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2023)
FIGURE 54 SANDOZ GROUP AG: COMPANY SNAPSHOT (2023)
